UBS Group’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

UBS Group’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-138,614	Closed	-$1.7M	–	11371
2022 Q4	$1.7M	Buy	138,614 +115,690	+505%	+$2.76M	﹤0.01%	3544
2022 Q3	$753K	Buy	22,924 +22,052	+2,529%	+$623K	﹤0.01%	3988
2022 Q2	$16K	Sell	872 -1,283	-60%	-$24.6K	﹤0.01%	7247
2022 Q1	$38K	Buy	+2,155	New	+$44.2K	﹤0.01%	6773

UBS Group's CINC Position: Q1 2023 in Review

UBS Group sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 138,614 shares — an estimated $1.7M sold.

UBS Group first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $1.7M in Q4 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

UBS Group reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
UBS Group sold 138,614 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $1.7M.
UBS Group first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
UBS Group's CinCor Pharma, Inc. Common Stock position peaked at $1.7M in Q4 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.